![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
|
ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Basic Trial Information
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
Phase
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
Type
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
Status
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
Age
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
Sponsor
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
Protocol IDs
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
Phase III
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
Treatment
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
Closed
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
21 and over
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
Pharmaceutical / Industry
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
ALFACELL-P30-302 NCI-V97-1273, NCT00003034
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
|
Objectives - Compare the efficacy of doxorubicin with or without Onconase in patients with malignant pleural or peritoneal mesothelioma.
- Compare the safety profile of these regimens in these patients.
- Compare the overall survival, progression-free survival, and quality of life of patients treated with these regimens.
Entry Criteria Disease Characteristics:
- Histologically confirmed malignant pleural or peritoneal mesothelioma
- Measurable or evaluable disease
- CALGB groups 1-4
- No CNS metastases
Prior/Concurrent Therapy:
Biologic therapy: Chemotherapy: - No more than one prior systemic chemotherapy regimen
- No prior doxorubicin
- At least 6 weeks since prior chemotherapy
Endocrine therapy: Radiotherapy: - Prior radiotherapy for progressive or recurrent disease
allowed except myocardium radiotherapy
Surgery: - Prior surgical resection allowed
Patient Characteristics:
Age: Performance status: Life expectancy: Hematopoietic: - WBC greater than 3,500/mm3
- Absolute neutrophil count at least 1,500/mm3
- Platelet count at least 100,000/mm3
Hepatic: - SGOT no greater than 2 times upper limit of normal
- Bilirubin no greater than 2 mg/dL
- PT and PTT normal
Renal: Cardiovascular: - No symptomatic New York Heart
Association class II-IV cardiovascular disease
- No congestive heart failure
- No angina pectoris
- No cardiac arrhythmias
- No uncontrolled hypertension
- No cerebrovascular disease
Metabolic: - No serum calcium, phosphate, electrolyte, or other metabolic
abnormalities, such as metabolic acidosis
Other: - Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No serious infection
- No uncontrolled psychosis or neurologic disease (e.g., seizure
disorders)
- No uncontrolled diabetes mellitus
- No other primary malignancy within the past 5 years except
nonmelanoma skin cancer
- No senility or emotional instability
Expected Enrollment 300A minimum of 300 patients will be accrued for this study. Outcomes Primary Outcome(s)Survival
Secondary Outcome(s)Objective response Time to best response Response duration
Outline This is a randomized, open-label, controlled, multicenter study.
Patients are stratified according to disease histology (epithelioid vs
nonepithelioid) and CALGB groups 1-4. Patients are randomized to 1 of 2
treatment arms. - Arm I: Patients receive Onconase IV over 30 minutes
weekly followed by doxorubicin IV. Treatment repeats every 3 weeks for at
least 6 courses in the absence of disease progression. Patients
demonstrating evidence of clinical response or stable disease may continue on
maintenance therapy with Onconase as a single agent until disease
progression.
- Arm II: Patients receive doxorubicin as in arm I for up to 6 courses.
Quality of life is assessed.
Trial Contact Information
Trial Lead Organizations Alfacell Corporation ![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) | Diane Scudiery, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) |
Registry Information | ![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) | Official Title | | ONCONASE Plus Doxorubicin Versus Doxorubicin For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen | ![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) | Trial Start Date | | 1997-05-15 | ![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) | Trial Completion Date | | 2008-02-15 (estimated) | ![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) | Registered in ClinicalTrials.gov | | NCT00003034 | ![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) | Date Submitted to PDQ | | 1997-05-20 | ![](https://webarchive.library.unt.edu/eot2008/20081015142643im_/http://www.cancer.gov/images/spacer.gif) | Information Last Verified | | 2007-10-11 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
![](images/spacer.gif) |